Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Arena Ready For FDA To Reconsider Weight-Loss Drug Lorcaserin

Jan 04 2012

• By Shirley Haley

Related Content

Obesity Drugs Go Back To The Drawing Board; FDA To Hold Advisory Cmte On CV Risk

Jun 03 2011

Arena Must Deal With Rat Neoplasms To Move Forward With <i>Lorqess</i>

Sep 20 2010

Approvability Of Arena's Lorcaserin Still Unclear

Nov 09 2010

FDA Issues Complete Response Letter for Arena's Lorcaserin

Oct 24 2010

Qnexa’s Second Advisory Committee Review: Smaller Indication, Still Big Safety Questions

Dec 23 2011

Obesity Drug Developers Aim To Navigate Regulatory Backroads

Apr 01 2011

Related Companies

Arena Pharmaceuticals, Inc.

Eisai Co., Ltd.

Vivus, Inc.

Orexigen Therapeutics, Inc.

Additional Topics

Advisory Committees Regulation Drug Approval Standards BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window